TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck Sharp & Dohme Corp. to study NOX-A12 combined with Keytruda and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The company was formerly known as NOXXON Pharma N.V. and changed its name to TME Pharma N.V. in July 2022. TME Pharma N.V. was founded in 1997 and is based in Berlin, Germany.

TME Pharma N.V.

TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. TME Pharma’s mission is to improve treatment outcomes for patients with cancer where TME significantly limits survival. The lead compound NOX-A12 acts in two distinct mechanisms of action, presenting great potential for developing this asset in various oncology indications. Currently, TME Pharma is focused on brain cancer (glioblastoma, GBM), with promising topline clinical results.NOXXON's Spiegelmer® platform has generated a proprietary pipeline of clinical-stage assets including its lead cancer candidate NOX-A12, which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD (NYSE: MRK) to study NOX-A12 combined with KEYTRUDA® (pembrolizumab) in pancreatic and colorectal cancer. NOXXON’s pipeline also contains NOX-E36, which targets other tumor microenvironment targets implicated in cancer spread and immune privilege of tumors.

	Mar '21	Jun '21	Sep '21	Dec '21	Mar '22	Jun '22	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Jun '24
net income	-3.38K -	-6.76M 199,900%	-3.85K 99.94%	-7.69M 199,900%	-5.16K 99.93%	-10.33M 199,900%	-2.40K 99.98%	-4.80M 199,900%	-1.83K 99.96%		-1.54M -	-1.54M 0%	-3.25M 111.11%
depreciation and amortization	17 -	34K 199,900%	16 99.95%	32K 199,900%	15 99.95%	30K 199,900%	31 99.90%	62K 199,900%	39 99.94%		33K -	33K 0%	66K 100%
deferred income tax
stock based compensation	55.50 -	55.50 0%	182 227.93%	182 0%	193 6.04%		101.50 -		100.50 -
change in working capital	-22.50 -	-145K 644,344.44%	15.50 100.01%	552K 3,561,190.32%	0.50 100.00%	1.42M 283,199,900%	-70.50 100.00%	-2.14M 3,029,687.23%	47 100.00%		71K -	71K 0%	-281K 495.77%
accounts receivables
inventory
accounts payables		-100K -		521K -		1.42M -		-2.00M -					-230K -
other working capital	-22.50 -	-45K 199,900%	15.50 100.03%	31K 199,900%	0.50 100.00%	1K 199,900%	-70.50 107.05%	-141K 199,900%	47 100.03%		71K -	71K 0%	-51K 171.83%
other non cash items	366 -	1.11M 303,178.69%	406 99.96%	197K 48,422.17%	2.03K 98.97%	3.02M 149,048.36%	-801.50 100.03%	585K 73,088.15%	-54 100.01%		414.50K -	414.50K 0%	726K 75.15%
net cash provided by operating activities	-2.96K -	-5.93M 199,933.73%	-3.23K 99.95%	-6.45M 199,931.00%	-2.93K 99.95%	-5.86M 199,934.14%	-3.14K 99.95%	-6.29M 200,218.27%	-1.70K 99.97%		-1.12M -	-1.12M 0%	-2.74M 144.27%
investments in property plant and equipment	-4.50 -	-9K 199,900%	-2.50 99.97%	-5K 199,900%	-4 99.92%	-8K 199,900%	-6.50 99.92%	-13K 199,900%	-9.50 99.93%				-4K -
acquisitions net
purchases of investments													-4K -
sales maturities of investments
other investing activites
net cash used for investing activites	-4.50 -	-9K 199,900%	-2.50 99.97%	-5K 199,900%	-4 99.92%	-8K 199,900%	-6.50 99.92%	-13K 199,900%	-9.50 99.93%				-8K -
debt repayment
common stock issued		9.32M -		2.20M -		4.44M -		2.94M -					3.27M -
common stock repurchased			-2 -	-1K 49,900%			-15 -	-29K 193,233.33%			-500 -	-500 0%	-3K 500%
dividends paid
other financing activites	4.65K -	4.65K 0%	1.10K 76.38%	1.10K 0%	2.21K 100.96%		1.45K -	-36K 2,584.47%	895 102.49%		738.50K -	738.50K 0%	-61K 108.26%
net cash used provided by financing activities	4.65K -	9.30M 199,921.50%	1.10K 99.99%	2.19M 199,991.16%	2.21K 99.90%	4.42M 199,945.28%	1.43K 99.97%	2.88M 200,597.35%	895 99.97%		738K -	738K 0%	3.20M 334.15%
effect of forex changes on cash			24.50 -	24.50 0%	-6.50 126.53%	-13K 199,900%	35 100.27%	70K 199,900%	-1.50 100.00%		1K -	1K 0%
net change in cash	1.68K -	3.37M 199,900%	-2.11K 100.06%	-4.21M 199,900%	-731.50 99.98%	-1.46M 199,900%	-1.68K 99.89%	-3.36M 199,900%	-813 99.98%		-381.50K -	-381.50K 0%	503K 231.85%
cash at beginning of period		10.30M -	13.67K 99.87%	13.67M 99,900%		9.46M -	7.99K 99.92%	7.99M 99,900%		4.63M -			2.20M -
cash at end of period	1.68K -	13.67M 812,140.05%	11.56K 99.92%	9.46M 81,678.09%	-731.50 100.01%	7.99M 1,092,786.26%	6.31K 99.92%	4.63M 73,298.27%	-813 100.02%	4.63M 570,087.70%	-381.50K 108.23%	-381.50K 0%	2.70M 808.52%
operating cash flow	-2.96K -	-5.93M 199,933.73%	-3.23K 99.95%	-6.45M 199,931.00%	-2.93K 99.95%	-5.86M 199,934.14%	-3.14K 99.95%	-6.29M 200,218.27%	-1.70K 99.97%		-1.12M -	-1.12M 0%	-2.74M 144.27%
capital expenditure	-4.50 -	-9K 199,900%	-2.50 99.97%	-5K 199,900%	-4 99.92%	-8K 199,900%	-6.50 99.92%	-13K 199,900%	-9.50 99.93%				-4K -
free cash flow	-2.97K -	-5.94M 199,933.68%	-3.23K 99.95%	-6.46M 199,930.97%	-2.93K 99.95%	-5.87M 199,934.09%	-3.15K 99.95%	-6.31M 200,217.61%	-1.71K 99.97%		-1.12M -	-1.12M 0%	-2.74M 144.62%

COM:TMEPHARMA

TME Pharma N.V.

Last Close

0.15

25/11 09:23

Market Cap

6.05M

Beta: -

Volume Today

744.63K

Avg: -

Preview